



Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		Application Number	10/807,911
		Filing Date	March 23, 2004
		First Named Inventor	L.Sai Latha Shankar
		Art Unit	1645
		Examiner Name	Not Yet Assigned
Sheet	1	of	2
		Attorney Docket Number	WTZ-010CPACN2

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/JK/	A1	5,444,095	08-22-1995	Tatton <i>et al.</i>	
	A2	5,767,164	06-16-1998	Tatton <i>et al.</i>	
	A3	5,844,003	12-01-1998	Tatton <i>et al.</i>	
/JK/	A4	6,492,427	12-10-2002	Shankar <i>et al.</i>	

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No.	Foreign Patent Document Country Code <sup>3</sup> -Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/JK/	A5	WO 96/40095 A1	12-19-1996	Harris, Richard Y.	
	A6	WO 96/22068 A2	07-25-1996	Somerset Pharmaceuticals	
	A7	WO 97/25421 A2	07-17-1997	Ciba Geigy AG	
/JK/	A8	WO 97/28791 A2	08-14-1997	University of Toronto	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the Indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>2</sup>
/JK/	A9	Bernheimer, H. <i>et al.</i> (1973) "Brain Dopamine and the Syndromes of Parkinson and Huntington. Clinical, Morphological and Neurochemical Correlations" Journal of the Neurological Sciences 29:415-455;			
	A10	Birkmayer, <i>et al.</i> (-)Deprenyl leads to prolongation of L-dopa efficacy in Parkinson's disease. Mod Probl Pharmacopsychiatry. 1983;19:170-6.			
	A11	Birkmayer, <i>et al.</i> Deprenyl prolongs the therapeutic efficacy of combined L-DOPA in Parkinson's disease. Adv Neurol. 1984;40:475-81.			
	A12	Birkmayer, <i>et al.</i> Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson's disease: a longterm study. J Neural Transm. 1985;64(2):113-27.			
	A13	Birkmayer, <i>et al.</i> The potentiation of the anti aknetic effect after L-dopa treatment by an inhibitor of MAO-B, Deprenil. J Neural Transm. 1975;36(3-4):303-26.			
	A14	Cedarbaum, <i>et al.</i> A double-blind crossover comparison of Sinemet CR4 and standard Sinemet 25/100 in patients with Parkinson's disease and fluctuating motor performance. J Neurol Neurosurg Psychiatry. 1989 Feb;52(2):207-12.			
/JK/	A15	Dorland's Illustrated Medical Dictionary, 28 <sup>th</sup> Supp. Edition, 1988, p. 1174.			

Examiner Signature	/Jennifer Kim/	Date Considered	03/20/2008
--------------------	----------------	-----------------	------------



Approved for use through 07/31/2006. OMB 0851-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, these instructions are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		Application Number	10/807,911
		Filing Date	March 23, 2004
		First Named Inventor	L Sai Latha Shankar
		Art Unit	1645
		Examiner Name	Not Yet Assigned
Sheet	2	of	2
		Attorney Docket Number	WTZ-010CPACN2

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/JK/	B1	Elizan, et al. Selegiline as an adjunct to conventional levodopa therapy in Parkinson's disease. Experience with this type B monoamine oxidase inhibitor in 200 patients. Arch Neurol. 1989 Dec;46(12):1280-3.	
	B2	Fischer, et al. Therapeutic efficacy of R-(-)-deprenyl as adjuvant therapy in advanced parkinsonism. J Neural Transm Suppl. 1987;25:137-47.	
	B3	Golbe, Lawrence I. Long-term efficacy and safety of deprenyl (selegiline) in advanced Parkinson's disease. Neurology. 1989 Aug;39(8):1109-11.	
	B4	Golbe, et al. Selegiline and Parkinson's disease. Protective and symptomatic considerations. Drugs. 1990 May;39(5):646-51.	
	B5	Lieberman, et al. Deprenyl versus placebo in Parkinson disease: a double-blind study. N Y State J Med. 1987 Dec;87(12):646-9.	
	B6	Mitrovic, et al. An in Vitro Model of Oligodendrocyte Destruction by Nitric Oxide and Its Relevance to Multiple Sclerosis. Methods. 1996 Dec;10(3):501-13.	
	B7	Parkinson Study Group. DATATOP: a multicenter controlled clinical trial in early Parkinson's disease. Arch Neurol. 1989 Oct;46(10):1052-60.	
	B8	The Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med. 1989 Nov 16;321(20):1364-71.	
	B9	Raine, Cedric. The Norton Lecture: a review of the oligodendrocyte in the multiple sclerosis lesion. J Neuroimmunol. 1997 Aug;77(2):135-52.	
	B10	Shankar, S.L. (1995) "R-(-)-Deprenyl Increases Survival and Process Complexity of Oligodendrocytes In Vitro" 25 <sup>th</sup> Annual Meeting of the Society for Neuroscience, San Diego, California, USA, November 11-16, 1995. Society for Neuroscience Abstracts 21(1-3):41.	
	B11	Sketris, et al. Drug therapy in multiple sclerosis: a study of Nova Scotia senior citizens. Clin Ther. 1996 Mar-Apr;18(2):303-18.	
↓	B12	Tatton, et al. Modulation of gene expression rather than monoamine oxidase inhibition: (-)-deprenyl-related compounds in controlling neurodegeneration. Neurology. 1996 Dec;47(6 Suppl 3):S171-83.	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Jennifer Kim/	Date Considered	03/20/2008
--------------------	----------------	-----------------	------------